解码自免疾病中的细胞因子网络从机制解析到治疗新突破

义翘神州CONTENT123401Wang

L

,

et

al.

/10.1111/joim.12395•••Balogh

L,

et

al.

/10.3389/fimmu.2024.1249500TDPDNCD4+/

CD8+TTCRTCR(ANA)95-99%85-95%ELISA/60-95%90-99%(RF)70-80%85-95%RA(C3,

C4)70-90%80-90%(ESR,

CRP)60-80%50-70%40-70%60-80%HLAPCR-SSP/90-99%70-95%80-95%95-99%X

/CT/MRI/70-90%80-95%/60-85%70-90%ELISA,,

ELISAELISA,RNAqPCR,RNAqPCR,

RNA,16S

rRNA//2011-20224.6%1500Journal

of

Clinical

Investigation20242.7-3.0%3100Global

EpidemiologyThyroiditisRASLEIBDMSPrevper

100kAutoimmune

Prev:

China

vs

US

(2020-2024)ChinaUS•2322/105.2•1000/109.656.4••2020-2024Aaron

H.

A,

et

al.

/10.1172/JCI178722.Mohamed-Ahmed

O,

et

al.

/10.1016/j.gloepi.2024.100158图片需替换2024755.320331242.85.69%/report/autoimmune-therapeutics-market2033

106https:///industry-

analysis/autoimmune-disease-diagnostics-industry2023

546.2%Clinical

trialsSource:/

(starting

date

from

01/01/2020

–

06/02/2025)955349863573961561542344517461154013131223967674627604531…………Source:

NCBI-PubMedCentral28084

30592

29448

27660

27369114762000040000Publication

Count(Autoimmune

Disease)2751291825652267244411262000400002020

2021

2022

2023

2024

2025Count

(Autoimme

Disease)Publication

Count(Autoimmune

Disease

&

Cytokine)02020

2021

2022

2023

2024

2025Count

(Autoimmune

Disease&Cytokine)Research

PapersSource:/

(starting

date

from

01/01/2020

–

06/02/2025)02ILIFNTNFCSF•••Farzana

Yasmeen,

et

al.

/10.3390/ijms25147666DiseasePro-inflammatoryAnti-inflammatoryCell

imbalanceKey

mechanismsRATNF-α,

IL-1β,

IL-6,

IL-17A,

IFN-γIL-10

decreased,

TGF-βimpairedTh1/Th17

increased,

TregdecreasedTNF-αalters

B10,synovitisSLETNF-α,

IL-6,

IFN-α,

IL-17,

1L-21IL-10

decreased,

TregimpairedTh1/Th2

imbalance,

Th17increasedlFN-α

overactive,autoantibodiesMSTNF-α,

IFN-γ,

IL-2,

IL-17,

GM-CSFTGF-β

decreased,

lL-10alteredTh1/Th17

high,

TregdeficientBlood-brain

barrierdisruptionT1DMIFN-γ,

IL-2,

TNF-α,

IL-17IL-10

&

Treg

decreasedTh1

&

Th17

high,

Tregreducedβ-cellautoimmunedestructionSSTNF-α,

IL-1β,

IL-6,

IFN-γAnti-inflammsignalingalteredTh1

dominance,

immunityincreasedGlandular

cellapoptosishighIBDTNF-α,

IL-1β,

IL-6,

IL-12,

IL-23IL-10

defect,Treg

impairedTh1/Th17

high,

TregdysfunctionIntestinalbarrierbreakdownBiomarkerRAPsoMSUCT1DCDSLEASSScPsALNMGIgANNMOILDIL-6TNF-αVEGFCXCL10IL-17CXCL8MCP-1IL-23HSP70TL1ATGF-βPDGFIFN-γIL-1βCXCL13RASLEIgANPsASNMOMSSScILDUCPsAT1D

LNCDMGBiomarkerRAPsoMSUCT1DCDSLEASSScPsALNMGIgANNMOILDIL-6TNF-αVEGFCXCL10IL-17CXCL8MCP-1IL-23HSP70TL1ATGF-βPDGFIFN-γIL-1βCXCL13RASLEIgANPsASNMOMSSScILDUCPsAT1D

LNCDMG03IL-12

x

IL-232024/11/29IL-23P19/IL23A2017/7/13IL-17A2016/3/22BAFF/BLyS/TNFSF13B2011/3/9TNF-alpha2009/4/24TNF-alpha2008/4/22TNF-alpha2002/12/31IL-12001/11/14BAFF/BLyS/TNFSF13BMS,

LN,

MG,

ILD,

SLE,

SSc,

IgAN,

NMOTNF-alphaRA,

Ps,

UC,

CD,

SLE,

ASIL-17APs,

MS,

UC,

LN,

AS,SScAPRIL/TNFSF13MS,

LN,

MG,

IgAN,

NMOIL-12Ps,

UC,

CD,

ASIL-23Ps,

UC,

CD,

ASIL-6RA,

ILD,CDJAK-STATJAK

JAK-STATCytokine

Signaling

Through

JAKs

and

Selectivity

of

JAKInhibitorsJAK/STAT

Signaling

PathwayFigure

adapted

from

“Cytokine

signalingthroughthe

JAK-STAT

pathway”,

by

BioR.Virtanen,

A.,

et

al.

/10.1038/s41584-024-01153-13IL-13

IL-31Rα

IL-36R12

TYK2•TNF-αTNFOX40TL1A•()GSKIL-17A/FIL-5IL-4depemokimabIL-33

IL-18••IRAK4

TSLPIL-17

TNFAlexandre

Fauconnier

et

al.

/10.1038/d41573-025-00061-7.04SEMA5ASEMA5AscFv(A)(B)(C)scFvELISAELISASEMA5A

scFvSEMA5A

scFvSEMA5ASEMA5APLXNB3Yang

Qin

et

al.

/10.1016/j.biopha.2023.115666(A)(B)(C)Biotinylated

HumanSEMA5A

Protein

(Sino

Biological(A)(A)Fluorescence

intensity

scores

for

kidneys

from

pristane-induced

lupus

mice

injected

with

GDF-15.(B-C)

GDF-15

treatment

reduced

the

production

ofautoantibodies.

Serum

levels

of

antinuclearantibodies

(ANA)

and

total

IgGin

pristane-induced

lupusmice

injected

with

GDF-15.Wang-Dong

Xu

et

al.

/10.3389/fimmu.2022.926373(B)(C)GDF-15Human

GDF-15

ProteinCat#:

10936-H01H(A)

pH

4.0-5.5Cathepsin

DmCatD2(B)

BDC-2.5

T(C)

BDC-2.5

TBDC-2.5

TmCatD2.5HIP2.5HIPpH4.0D0

1

2

24

48

72L

Z

B

S

H24Cathepsin

1Mouse

Cathepsin

D

(Cat#:

50127-M08H)

Mouse

Cathepsin

L

(Cat#:

50015-M08H)Mouse

CathepsinZ

(Cat#:

50089-M08H)

Mouse

Cathepsin

B

(Cat#:

50084-M08H)Mouse

Cathepsin

S

(Cat#:

50769-M08H)

Mouse

Cathepsin

H

(Cat#:

50619-M08H)CSamantha

A.

Crawford

et

al.

/10.2337/db22-0303SPRAKT1DHEKD

1.16310-5Xiao

Ma

et

al.

/10.3390/molecules29174031AKT1Human

AKT1

ProteinCat#:10763-H08B(A)AhRPKCθ(B)

RORγt

IKKβ(B)Pull-downHuai-Chia

Chuang

et

al.

/10.1126/sciadv.aat5401(A)IL-17AGST-PKCθ

(Cat#:

P74-10G)

and

GST-IKKβ

Proteins

(Cat#:

I03-18G)

(SignalChemKIR2DL1/2/3MTX-101MTX-101

MTX-101CD8αBLI

BLIKIR/Ly49F

CD8Jennifer

L.

Gardell

et

al.

/10.3389/fimmu.2024.1452537CD8

T

Treg

MTX-101(B)Human

KIR2DL1

(Cat#:

13145-H08H)

Human

KIR2DL3

(Cat#:

12828-H08H)

Human

CD8α

(Cat#:

10980-H08S)

Mouse

CD8α

(Cat#:

50389-M08H)

Cynomolgus

CD8α-Fc

(Cat#:

90888-C02H)(A)

(C)•••/category/solutions/autoimmune-diseases/research/cytokinesInterferongamma

secretion

by

humannaturalkiller

lymphoma

NK-92

cells.Purity:

≥

95

%

as

determined

by

SDS-PAGE&

SEC-HPLC.Human

IL-12

Protein,

GMP

grade

(Cat#:

GMP-CT011-H08H)Human

mouse

monkeyGMP

RU